{"ID": "531C114FC8D4E60ADAFFC213898FB77C", "URL": "https://www.ema.europa.eu/documents/product-information/infanrix-penta-epar-product-information_en.pdf", "Product_Name": "Infanrix Penta", "Full_Content": "Me\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nANNEX I \n \n\nSUMMARY OF PRODUCT CHARACTERISTICS \n \n\n1 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n1. NAME OF THE MEDICINAL PRODUCT \n \nInfanrix Penta, Suspension for injection  \nDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), \npoliomyelitis (inactivated) (IPV) vaccine (adsorbed) \n \n \n2. QUALITATIVE AND QUANTITATIVE COMPOSITION \n \n1 dose (0.5 ml) contains: \n \nDiphtheria toxoid1 not less than 30 IU \nTetanus toxoid1 not less than 40 IU \nBordetella pertussis antigens \n Pertussis toxoid1  25 micrograms \n\nFilamentous Haemagglutinin1  25 micrograms \nPertactin1 8 micrograms \nHepatitis B surface antigen2,3 10 micrograms \n\nPoliovirus (inactivated)  \n type 1 (Mahoney strain)4 40 D-antigen unit \n\ntype 2 (MEF-1 strain) 4 8 D-antigen unit \ntype 3 (Saukett strain) 4 32 D-antigen unit \n\n \n1adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+  \n2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology \n3adsorbed on aluminium phosphate (AlPO4) 0.2 milligrams Al3+ \n4propagated in VERO cells \n \nFor a full list of excipients, see section 6.1. \n \n \n3. PHARMACEUTICAL FORM \n \nSuspension for injection  \nInfanrix Penta is a turbid white suspension. \n \n \n4. CLINICAL PARTICULARS \n \n4.1 Therapeutic indications \n \nInfanrix Penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, \npertussis, hepatitis B and poliomyelitis.  \n \n \n4.2 Posology and method of administration \n \nPosology \n \nPrimary vaccination: \n \nThe primary vaccination schedule consists of three doses of 0.5 ml (such as 2, 3, 4 months; 3, 4, 5 \nmonths; 2, 4, 6 months) or two doses (such as 3, 5 months). There should be an interval of at least 1 \nmonth between doses.  \n \n\n2 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\nThe Expanded Program on Immunisation schedule (at 6, 10, 14 weeks of age) may only be used if a \ndose of hepatitis B vaccine has been given at birth. \n \nLocally established immunoprophylactic measures against hepatitis B should be maintained. \n \nWhere a dose of hepatitis B vaccine is given at birth, Infanrix Penta can be used as a replacement for \nsupplementary doses of hepatitis B vaccine from the age of six weeks. If a second dose of hepatitis B \nvaccine is required before this age, monovalent hepatitis B vaccine should be used. \n \nBooster vaccination: \n \nAfter a vaccination with 2 doses (e.g. 3, 5 months) of Infanrix Penta a booster dose must be given at \nleast 6 months after the last priming dose, preferably between 11 and 13 months of age. \n \nAfter vaccination with 3 doses (e.g. 2, 3, 4 months; 3, 4, 5 months; 2, 4, 6 months) of Infanrix Penta a \nbooster dose must be given at least 6 months after the last priming dose and preferably before 18 \nmonths of age. \n \nBooster doses should be given in accordance with the official recommendations. \n \nInfanrix Penta can be considered for the booster if the composition is in accordance with the official \nrecommendations. \n \nPaediatric population \n \nThere is no relevant use of Infanrix Penta in children over 36 months. \n \nMethod of administration \n \nInfanrix Penta is for deep intramuscular injection, preferably at alternating sites for subsequent \ninjections. \n \n4.3 Contraindications \n \nHypersensitivity to the active substances or to any of the excipients or neomycin and polymyxin. \n \nHypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or polio \nvaccines. \n \nInfanrix Penta is contraindicated if the infant has experienced an encephalopathy of unknown \naetiology, occurring within 7 days following previous vaccination with pertussis containing vaccine. \nIn these circumstances pertussis vaccination should be discontinued and the vaccination should be \ncontinued with diphtheria-tetanus, hepatitis B and polio vaccines. \n \nAs with other vaccines, administration of Infanrix Penta should be postponed in subjects suffering \nfrom acute severe febrile illness. The presence of a minor infection is not a contraindication. \n \n4.4 Special warnings and precautions for use \n \nVaccination should be preceded by a review of the medical history (especially with regard to previous \nvaccination and possible occurrence of undesirable events) and a clinical examination. \n \nIf any of the following events are known to have occurred in temporal relation to receipt of pertussis-\ncontaining vaccine, the decision to give further doses of pertussis-containing vaccines should be \ncarefully considered: \n\n\u2022 Temperature of \u2265 40.0 C within 48 hours, not due to another identifiable cause; \n\n3 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n\u2022 Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of \nvaccination; \n\n\u2022 Persistent, inconsolable crying lasting \u2265 3 hours, occurring within 48 hours of vaccination; \n\u2022 Convulsions with or without fever, occurring within 3 days of vaccination. \n\nThere may be circumstances, such as a high incidence of pertussis, when the potential benefits \noutweigh possible risks. \n \nAs for any vaccination, the risk-benefit of immunising with Infanrix Penta or deferring this \nvaccination should be weighed carefully in an infant or in a child suffering from a new onset or \nprogression of a severe neurological disorder. \n \nAs with all injectable vaccines, appropriate medical treatment and supervision should always be \nreadily available in case of a rare anaphylactic event following the administration of the vaccine.  \n \nInfanrix Penta should be administered with caution to subjects with thrombocytopenia or a bleeding \ndisorder since bleeding may occur following an intramuscular administration to these subjects. \n \nInfanrix Penta should under no circumstances be administered intravascularly or intradermally. \n \nInfanrix Penta will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, \nClostridium tetani, Bordetella pertussis, hepatitis B virus or poliovirus. However, it can be expected \nthat hepatitis D will be prevented by immunisation as hepatitis D (caused by the delta agent) does not \noccur in the absence of hepatitis B infection. \n \nAs with any vaccine, a protective immune response may not be elicited in all vaccinees (see section \n5.1). \n \nA history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome \n(SIDS) do not constitute a contraindication for the use of Infanrix Penta. Vaccinees with a history of \nfebrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days \npost vaccination. \n \nHIV infection is not considered as a contraindication. The expected immunological response may not \nbe obtained after vaccination of immunosuppressed patients. \n \nThe potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered \nwhen administering the primary immunisation series to very premature infants (born \u2264 28 weeks of \ngestation) and particularly for those with a previous history of respiratory immaturity. \nAs the benefit of the vaccination is high in this group of infants, vaccination should not be withheld or \ndelayed.  \n \n4.5 Interaction with other medicinal products and other forms of interaction \n \nClinical studies have demonstrated that Infanrix Penta can be administered simultaneously with \nHaemophilus influenzae type b vaccines. In these clinical studies, the injectable vaccines were given at \ndifferent injection sites. \n \nThere are no data with regard to the efficacy and safety of simultaneous administration of Infanrix \nPenta and Measles-Mumps-Rubella vaccine. \n \nAs with other vaccines, it may be expected that in patients receiving immunosuppressive therapy an \nadequate response may not be achieved.   \n \n4.6 Fertility, pregnancy and lactation \n \nAs Infanrix Penta is not intended for use in adults, adequate human data on use during pregnancy or \nlactation and adequate animal reproduction studies are not available. \n\n4 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n4.7 Effects on ability to drive and use machines   \n \nNot relevant. \n \n4.8 Undesirable effects \n \n\u2022 Clinical trials \n \nThe safety profile presented below is based on data from more than 10,000 subjects. In virtually all \ninstances, Infanrix Penta was administered at the same time as a Hib vaccine. \n \nAs has been observed for DTPa and DTPa-containing combinations, an increase in local \nreactogenicity and fever was reported after booster vaccination with Infanrix Penta with respect to the \nprimary course. \n \n\n- Tabulated summary of adverse reactions (clinical trials): \n \nWithin each frequency grouping, undesirable effects are presented in order of decreasing seriousness. \n \nFrequencies per dose are defined as follows: \n \nVery common: (\u2265 1/10) \nCommon: (\u22651/100 to <1/10) \nUncommon: (\u22651/1,000 to <1/100) \nRare:  (\u22651/10,000 to <1/1,000) \nVery rare: (<1/10,000) \n \nNervous system disorders: \nUncommon: somnolence \nVery rare: convulsions (with or without fever) \n \nRespiratory, thoracic and mediastinal disorders\nUncommon: cough \n \nGastrointestinal disorders: \nCommon: diarrhoea, vomiting \n \nSkin and subcutaneous tissue disorders\nUncommon: dermatitis, rash \nVery rare: urticaria \n \nMetabolism and nutrition disorders \nVery common: appetite lost \n \nGeneral disorders and administration site conditions: \nVery common: fever \u2265 38\u00b0C, local swelling at the injection site (\u2264 50 mm), fatigue, pain, redness \nCommon: fever >39.5\u00b0C, local swelling at the injection site (> 50 mm)*, injection site reactions, \nincluding induration  \nUncommon: diffuse swelling of the injected limb, sometimes involving the adjacent joint* \n \nPsychiatric disorders: \nVery common: crying abnormal, irritability, restlessness \nUncommon: nervousness \n \n\n5 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n\u2022 Post-marketing surveillance \n \nNervous system disorders: \nCollapse or shock-like state (hypotonic-hyporesponsiveness episode) \n \nRespiratory, thoracic and mediastinal disorders: \nApnoea [see section 4.4 for apnoea in very premature infants (\u2264 28 weeks of gestation)]  \n \nGeneral disorders and administration site conditions: \nSwelling of the entire injected limb* \n \nImmune system disorders \nAllergic reactions, including anaphylactic and anaphylactoid reactions  \n \n\u2022 Experience with hepatitis B vaccine: \n \nIn extremely rare cases, paralysis, neuropathy, Guillain-Barr\u00e9 syndrome, encephalopathy, encephalitis \nand meningitis have been reported.  The causal relationship to the vaccine has not been established. \nThrombocytopenia has been reported with hepatitis B vaccine. \n \n* Children primed with acellular pertussis vaccines are more likely to experience swelling reactions \nafter booster administration in comparison with children primed with whole cell vaccines.  These \nreactions resolve over an average of 4 days. \n \n4.9 Overdose \n \nNo case of overdose has been reported. \n \n \n5. PHARMACOLOGICAL PROPERTIES \n \n5.1 Pharmacodynamic properties \n \nPharmaco-therapeutic group: Bacterial and viral vaccines combined, ATC code J07CA12 \n \nResults obtained in the clinical studies for each of the components are summarised in the tables below:  \n \nPercentage of subjects with antibody titres \u2265 assay cut-off one month after primary vaccination \nwith Infanrix Penta \n\n \nAntibody \n(cut-off) \n\n3-5 \nmonths \nN= 168 \n\n6-10-14  \nweeks \n\nN= 362 \n\n1.5-3.5-6 \nmonths \nN= 55 \n\n2-3-4 \nmonths \nN= 326 \n\n2-4-6 \nmonths \n\nN= 1146) \n\n3-4-5 \nmonths \nN= 884 \n\n3-4.5-6 \nmonths \nN=554 \n\nAnti-diphtheria  \n(0.1 IU/ml) \u2020 \n\n97.6 99.2 100 99.7 99.7 99.3 100 \n\nAnti-tetanus \n(0.1 IU/ml) \u2020 \n\n99.4 100 100 100 100 99.4 100 \n\nAnti-PT \n(5 EL.U/ml) \n\n100 99.7 100 100 99.7 99.4 100 \n\nAnti-FHA  \n(5 EL.U/ml) \n\n100 99.4 100 100 100 99.5 100 \n\nAnti-PRN \n(5 EL.U/ml) \n\n100 100 100 100 99.8 99.5 100 \n\nAnti-HBs \n(10 mIU/ml) \u2020 \n\n96.8 98.7* 100 98.4 99.4 98.2 99.6 \n\nAnti-Polio type 1 \n(1/8 dilution) \u2020 \n\n97.4 99.4 ND 99.6 99.7 99.5 100 \n\n6 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\nAnti-Polio type 2 \n(1/8 dilution) \u2020 \n\n94.7 99.2 ND 97.1 99.6 99.5 100 \n\nAnti-Polio type 3 \n(1/8 dilution) \u2020 \n\n99.3 99.4 ND 99.6 99.9 99.5 100 \n\nN = number of subjects \nND = not determined \n* in a subgroup of infants not administered hepatitis B vaccine at birth, 80.2% of subjects had anti-\nHBs titres \u2265 10 mIU/ml \n\u2020 cut-off accepted as indicative of protection \n \nPercentage of subjects with antibody titres \u2265 assay cut-off one month after booster vaccination \nwith Infanrix Penta \nAntibody \n(cut-off) \n\nBooster vaccination at \n11/12 months of age \n\nfollowing a 3-5 month \nprimary course \n\nN = 168 \n\nBooster vaccination \nduring the second \n\nyear of life following a \nthree dose primary \n\ncourse \nN = 350 \n\nAnti-diphtheria \n(0.1 IU/ml) \u2020 \n\n100 100 \n\nAnti-tetanus \n(0.1 IU/ml) \u2020 \n\n100 100 \n\nAnti-PT \n(5 EL.U/ml) \n\n100 99.7 \n\nAnti-FHA \n(5 EL.U/ml) \n\n100 99.7 \n\nAnti-PRN \n(5 EL.U/ml) \n\n100 99.7 \n\nAnti-HBs \n(10 mIU/ml) \u2020 \n\n100 98.8 \n\nAnti-Polio type 1 \n(1/8 dilution) \u2020 \n\n100 99.7 \n\nAnti-Polio type 2 \n(1/8 dilution) \u2020 \n\n100 100 \n\nAnti-Polio type 3 \n(1/8 dilution) \u2020 \n\n100 100 \n\nN = number of subjects \n\u2020 cut-off accepted as indicative of protection \n \nAs the immune response to pertussis antigens following Infanrix Penta administration is equivalent to \nthat of Infanrix, the protective efficacy of the two vaccines is expected to be equivalent. \n\n \nThe clinical protection of the pertussis component of Infanrix, against WHO-defined typical pertussis \n(\u2265 21 days of paroxysmal cough) was demonstrated in: \n \n- a prospective blinded household contact study performed in Germany (3, 4, 5 months schedule). \n\nBased on data collected from secondary contacts in households where there was an index case \nwith typical pertussis, the protective efficacy of the vaccine was 88.7%. \n \n\n- a NIH sponsored efficacy study performed in Italy (2, 4, 6 months schedule). The vaccine \nefficacy was found to be 84%. In a follow-up of the same cohort, the efficacy was confirmed up \nto 60 months after completion of primary vaccination without administration of a booster dose \nof pertussis. \n\n \nResults of long term follow-up in Sweden demonstrate that acellular pertussis vaccines are efficacious \nin infants when administered according to the 3 and 5 months primary vaccination schedule, with a \n\n7 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\nbooster dose administered at approximately 12 months. However, data indicate that protection against \npertussis may be waning at 7-8 years of age with this 3-5-12 months schedule. This suggests that a \nsecond booster dose of pertussis vaccine is warranted in children aged 5-7 years who have previously \nbeen vaccinated following this particular schedule. \n \nProtective antibodies against hepatitis B have been shown to persist for at least 3.5 years in more than \n90% of children administered four doses of a combined vaccine containing the same HBs antigen as \nInfanrix Penta. Antibody levels were not different from what was observed in a parallel cohort \nadministered 4 doses of monovalent hepatitis B vaccine. \n \n5.2 Pharmacokinetic properties \n \nEvaluation of pharmacokinetic properties is not required for vaccines. \n \n5.3 Preclinical safety data \n \nNon-clinical data reveal no special hazard for humans based on conventional studies of safety, specific \ntoxicity, repeated dose toxicity and compatibility of ingredients. \n \n \n6. PHARMACEUTICAL PARTICULARS \n \n6.1 List of excipients \n \nSodium chloride (NaCl) \nMedium 199 containing principally amino acids, mineral salts, vitamins  \nWater for injections \n \nFor adjuvants, see section 2. \n \n6.2 Incompatibilities \n \nIn the absence of compatibility studies, this medicinal product must not be mixed with other medicinal \nproducts. \n \n6.3 Shelf-life \n \n3 years. \n \nUpon removal from the refrigerator, the vaccine is stable for 8 hours at 21\u00b0C. \n \n6.4 Special precautions for storage \n \nStore in a refrigerator (2\u00b0C - 8\u00b0C). \nDo not freeze. \n \nStore in the original package, in order to protect from light. \n \n6.5 Nature and contents of container \n \n0.5 ml of suspension in a pre-filled syringe (type I glass) with plunger stoppers (butyl). \n \nPack sizes of 1, 10, 20 and 50 with or without needles. \n \nNot all pack sizes may be marketed. \n \n\n8 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n6.6  Special precautions for disposal and other handling \n \nUpon storage, a white deposit and clear supernatant may be observed. This does not constitute a sign \nof deterioration. \n \nThe syringe should be well shaken in order to obtain a homogeneous turbid white suspension. \n \nThe DTPa-HBV-IPV suspension should be inspected visually for any foreign particulate matter and/or \nabnormal physical appearance. In the event of either being observed, discard the vaccine.  \n \nAny unused product of waste material should be disposed of in accordance with local requirements. \n \n \n7. MARKETING AUTHORISATION HOLDER \n \nGlaxoSmithKline Biologicals s.a. \nRue de l'Institut 89 \nB-1330 Rixensart, Belgium \n \n \n8.  MARKETING AUTHORISATION NUMBERS \n \nEU/1/00/153/001 \nEU/1/00/153/002 \nEU/1/00/153/003 \nEU/1/00/153/004 \nEU/1/00/153/005 \nEU/1/00/153/006 \nEU/1/00/153/007 \nEU/1/00/153/008 \nEU/1/00/153/009 \nEU/1/00/153/010 \n \n \n9.  DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION \n \nDate of first authorisation: 23 October 2000 \nDate of latest renewal: 23 October 2005 \n \n \n10. DATE OF REVISION OF THE TEXT \n \n \n \n \nDetailed information on this medicinal product is available on the website of the European Medicines \nAgency http://www.ema.europa.eu \n\n9 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nANNEX II \n \n\nA. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND \nMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR \nBATCH RELEASE \n\n \nB.  CONDITIONS OF THE MARKETING AUTHORISATION \n \n\n10 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nA. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND \n\nMANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH \nRELEASE  \n\n \nName and address of the manufacturers of the biological active substances \n \nGlaxoSmithKline  Biologicals s.a. \nRue de l\u2019Institut 89, \n1330 Rixensart \nBelgium \n \nNovartis Vaccines and Diagnostics GmbH & Co. KG \nEmil-von-Behring-Str. 76, \nD-35041 Marburg \nGermany \n \nName and address of the manufacturer responsible for batch release \n \nGlaxoSmithKline Biologicals s.a. \nRue de l\u2019Institut 89, \n1330 Rixensart \nBelgium \n \n \nB. CONDITIONS OF THE MARKETING AUTHORISATION \n \n\u2022 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON \n\nTHE MARKETING AUTHORISATION HOLDER \n \nMedicinal product subject to medical prescription. \n \n\u2022 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND \n\nEFFECTIVE USE OF THE MEDICINAL PRODUCT \n \nNot applicable. \n \n\u2022 OTHER CONDITIONS \n \nPharmacovigilance system \nThe MAH must ensure that the system of pharmacovigilance, as described in version 3.06 \npresented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before \nand whilst the product is on the market. \n \nPSURs \nThe holder of marketing authorisation will submit 2-yearly PSURs. \n \n \nThe holder of the marketing authorisation must inform the European Commission about the marketing \nplans for the medicinal product authorised by this decision. \n \nOfficial batch release: in accordance with Article 114 of Directive 2001/83/EC as amended, the \nofficial batch release will be undertaken by a state laboratory or a laboratory designated for that \npurpose. \n\n11 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nANNEX III \n \n\nLABELLING AND PACKAGE LEAFLET \n \n\n12 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nA. LABELLING \n\n13 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nPARTICULARS TO APPEAR ON THE OUTER PACKAGING  \n1 PRE-FILLED SYRINGE WITHOUT NEEDLE \n10 PRE-FILLED SYRINGES WITHOUT NEEDLES \n20 PRE-FILLED SYRINGES WITHOUT NEEDLES \n50 PRE-FILLED SYRINGES WITHOUT NEEDLES \n1 PRE-FILLED SYRINGE WITH 1 NEEDLE \n10 PRE-FILLED SYRINGES WITH 10 NEEDLES \n20 PRE-FILLED SYRINGES WITH 20 NEEDLES \n50 PRE-FILLED SYRINGES WITH 50 NEEDLES \n1 PRE-FILLED SYRINGE WITH 2 NEEDLES \n10 PRE-FILLED SYRINGES WITH 20 NEEDLES \n \n \n1. NAME OF THE MEDICINAL PRODUCT \n \nInfanrix Penta, Suspension for injection \nDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), \npoliomyelitis (inactivated) (IPV) vaccine (adsorbed) \n \n \n2. STATEMENT OF ACTIVE SUBSTANCE(S) \n \n1 dose (0.5 ml): \nDiphtheria toxoid1  \u2265 30 IU \nTetanus toxoid1  \u2265 40 IU \nBordetella pertussis antigens  \n(Pertussis toxoid1, Filamentous haemagglutinin1, Pertactin1) 25, 25, 8 micrograms \nHepatitis B surface antigen2 10 micrograms \nPoliovirus (inactivated) type 1, 2, 3 40, 8, 32 DU \n \n1adsorbed on Al(OH)3 0.5 milligrams Al3+\n2adsorbed on AlPO4 0.2 milligrams Al3+ \n \n \n3. LIST OF EXCIPIENTS \n \nSodium chloride  \nMedium 199 containing principally amino acids, mineral salts, vitamins \nWater for injections \n \n \n4. PHARMACEUTICAL FORM AND CONTENTS \n \nSuspension for injection \n1 pre-filled syringe \n1 dose (0.5 ml) \n \n10 pre-filled syringes  \n10 x 1 dose (0.5 ml) \n \n20 pre-filled syringes  \n20 x 1 dose (0.5 ml) \n \n50 pre-filled syringes  \n\n14 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n50 x 1 dose (0.5 ml) \n \n1 pre-filled syringe + 1 needle \n1 dose (0.5 ml) \n \n10 pre-filled syringes + 10 needles \n10 x 1 dose (0.5 ml) \n \n20 pre-filled syringes + 20 needles \n20 x 1 dose (0.5 ml) \n \n50 pre-filled syringes + 50 needles \n50 x 1 dose (0.5 ml) \n \n1 pre-filled syringe + 2 needles \n1 dose (0.5 ml) \n \n10 pre-filled syringes + 20 needles \n10 x 1 dose (0.5 ml) \n \n \n5. METHOD AND ROUTE(S) OF ADMINISTRATION \n \nRead the package leaflet before use \nIntramuscular use \nShake before use \n \n \n6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT \n\nOF THE REACH AND SIGHT OF CHILDREN \n \nKeep out of the reach and sight of children \n \n \n7. OTHER SPECIAL WARNING(S), IF NECESSARY \n \n \n8. EXPIRY DATE \n \nEXP: MM/YYYY \n \n \n9. SPECIAL STORAGE CONDITIONS \n \nStore in a refrigerator  \nDo not freeze \nStore in the original package in order to protect from light \n \n \n10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS \n\nOR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF \nAPPROPRIATE \n\n \n \n11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER \n\n15 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nGlaxoSmithKline Biologicals s.a. \nRue de l\u2019Institut 89 \nB-1330 Rixensart, Belgium \n \n \n12. MARKETING AUTHORISATION NUMBER(S) \n \nEU/1/00/153/001 - 1 pre-filled syringe without needle  \nEU/1/00/153/002 - 10 pre-filled syringes without needles \nEU/1/00/153/003 - 20 pre-filled syringes without needles \nEU/1/00/153/004 - 50 pre-filled syringes without needles \nEU/1/00/153/005 - 1 pre-filled syringe with 1 needle \nEU/1/00/153/006 - 10 pre-filled syringes with 10 needles \nEU/1/00/153/007 - 20 pre-filled syringes with 20 needles \nEU/1/00/153/008 - 50 pre-filled syringes with 50 needles \nEU/1/00/153/009 - 1 pre-filled syringe with 2 needles \nEU/1/00/153/010 - 10 pre-filled syringes with 20 needles \n \n13. BATCH NUMBER \n \nLOT: \n \n \n14. GENERAL CLASSIFICATION FOR SUPPLY \n \nMedicinal product subject to medical prescription \n \n \n15. INSTRUCTIONS ON USE \n \n \n16. INFORMATION IN BRAILLE \n \nJustification for not including Braille accepted \n \n\n16 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nMINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS \n \n \n1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION \n \nInfanrix Penta \nSuspension for injection \nDTPa-HBV-IPV \nIM \n \n \n2. METHOD OF ADMINISTRATION \n \n \n3. EXPIRY DATE \n \nEXP  \n \n \n4. BATCH NUMBER \n \nLOT: \n \n \n5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT \n \n1 dose (0.5 ml) \n \n \n6. OTHER \n \n\n17 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\nB. PACKAGE LEAFLET \n \n\n18 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nPACKAGE LEAFLET: INFORMATION FOR THE USER \n\n \nInfanrix Penta, Suspension for injection \n\nDiphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), \npoliomyelitis (inactivated) (IPV) vaccine (adsorbed) \n\n \nRead all of this leaflet carefully before your child receives this vaccine. \n\u2022 Keep this leaflet. You may need to read it again. \n\u2022 If you have any further questions, ask your doctor or your pharmacist. \n\u2022 This vaccine has been prescribed for your child. Do not pass it on to others. \n\u2022 If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, \n\nplease tell your doctor or pharmacist. \n \nIn this leaflet: \n1.  What Infanrix Penta is and what it is used for \n2. Before your child receives Infanrix Penta \n3. How Infanrix Penta is given \n4. Possible side effects \n5. How to store Infanrix Penta \n6. Further information \n \n \n1.   WHAT INFANRIX PENTA IS AND WHAT IT IS USED FOR \n \nInfanrix Penta is a vaccine used to protect your child again five diseases:  \n\u2022 Diphtheria - a serious bacterial infection that mainly affects the airways and sometimes the skin. \n\nThe airways become swollen causing serious breathing problems and sometimes suffocation. The \nbacteria also release a poison. This can cause nerve damage, heart problems, and even death. \n\n \n\u2022 Tetanus - tetanus bacteria enter the body through cuts, scratches or wounds in the skin. Wounds \n\nthat are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have \nsoil, dust, horse manure or wood splinters in them. The bacteria release a poison. This can cause \nmuscle stiffness, painful muscle spasms, fits and even death. The muscle spasms can be strong \nenough to cause bone fractures of the spine. \n\n \n\u2022 Whooping cough (Pertussis) - a highly infectious illness that affects the airways. It causes severe \n\ncoughing that may lead to problems with breathing. The coughing often has a \u201cwhooping\u201d sound. \nThe cough may last for one to two months or longer. Whooping cough can also cause ear \ninfections, chest infections (bronchitis) which may last a long time, lung infections (pneumonia), \nfits, brain damage and even death.   \n\n \n\u2022 Hepatitis B - is caused by the hepatitis B virus. It makes the liver swollen. The virus is found in \n\nbody fluids such as in the vagina, blood, semen, or spit (saliva) of infected people. \n \n\u2022 Polio - a viral infection. Polio is often only a mild illness. However, sometimes it can be very \n\nserious and cause permanent damage or even death. Polio can make the muscles unable to move \n(paralysis). This includes the muscles needed for breathing and walking. The arms or legs affected \nby the disease may be painfully twisted (deformed). \n\n \nHow the vaccine works \n\u2022 Infanrix Penta helps your child\u2019s body make its own protection (antibodies). This will protect your \n\nchild against these diseases. \n\u2022 As with all vaccines, Infanrix Penta may not fully protect all children who are vaccinated. \n\u2022 The vaccine cannot cause the diseases that it protects your child from. \n \n\n19 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \n2.   BEFORE YOUR CHILD RECEIVES INFANRIX PENTA \n \nInfanrix Penta should not be given if: \n \n\u2022 your child is allergic (hypersensitive) to  \n\n- Infanrix Penta, or any ingredients in Infanrix Penta (listed in Section 6)  \n- neomycin or polymyxin (antibiotics). \n\nSigns of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the \nface or tongue. \n\n\u2022 your child has had an allergic reaction to any vaccine against diphtheria, tetanus, whooping \ncough, hepatitis B or polio. \n\n\u2022 your child has had problems of the nervous system within 7 days after previous vaccination \nwith a vaccine against whooping cough. \n\n\u2022 your child has a severe infection with a high temperature (over 38\u00b0C).  \nA minor infection such as a cold should not be a problem, but talk to your doctor first. \n\n \nInfanrix Penta should not be given if any of the above apply to your child. If you are not sure, talk to \nyour doctor or pharmacist before your child is given Infanrix Penta. \n \nTake special care with Infanrix Penta \n \nCheck with your doctor or pharmacist before your child is given this vaccine if: \n \n\u2022 after previously having Infanrix Penta or another vaccine against whooping cough, your child \n\nhad any problems, especially:  \n- a high temperature (over 40\u00b0C) within 48 hours of vaccination \n- a collapse or \u2018shock-like\u2019 state within 48 hours of vaccination \n- persistent crying lasting 3 hours or more within 48 hours of vaccination \n- fits with or without a high temperature within 3 days of vaccination \n\n\u2022 your child has an undiagnosed or progressive disease of the brain or epilepsy which is not \ncontrolled. After control of the disease the vaccine can be given. \n\n\u2022 your child has a bleeding problem or bruises easily \n\u2022 your child tends to have fits when they have a fever, or if there is a history of this in the family. \nIf any of the above apply to your child (or you are not sure), talk to your doctor or pharmacist before \nyour child is given Infanrix Penta. \n \nUsing other medicines or vaccines \nPlease tell your doctor if your child is taking or has recently taken any other medicines, including \nmedicines obtained without a prescription or has recently had any other vaccine. \n \nImportant information about some of the ingredients of Infanrix Penta \nThis vaccine contains neomycin and polymyxin (antibiotics). Please tell your doctor if your child has \nhad an allergic reaction to these ingredients. \n \n \n3.  HOW INFANRIX PENTA IS GIVEN \n \nHow much is given \n\u2022 Your child will have a total of two or three injections with at least 1 month between each injection.  \n\u2022 You will be told by the doctor or nurse when your child should come back for their next injections. \n\u2022 If additional injections (boosters) are necessary, the doctor will tell you. \n\n \nHow the vaccine is given \n\u2022 Infanrix Penta will be given as an injection into a muscle.   \n\u2022 The vaccine should never be given into a blood vessel or into the skin. \n\n20 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nIf your child misses a dose \n\u2022 If your child misses an injection which is due, it is important that you make another appointment. \n\u2022 Make sure your child finishes the complete vaccination course. If not, your child may not be \n\nfully protected against the diseases. \n \n \n4.   POSSIBLE SIDE EFFECTS \n \nLike all medicines, Infanrix Penta can cause side effects, although not everybody gets them. The \nfollowing side effects may happen with this vaccine: \n \nAllergic reactions \nIf your child has an allergic reaction, see your doctor straight away. The signs may include: \n\u2022 rashes that may be itchy or blistering \n\u2022 swelling of the eyes and face \n\u2022 difficulty in breathing or swallowing \n\u2022 a sudden drop in blood pressure and loss of consciousness. \nThese signs usually start very soon after the injection has been given. Talk to a doctor straight away if \nthey happen after leaving the doctor\u2019s surgery. \n \nSee your doctor straight away if your child has any of the following serious side effects: \n\u2022 collapse \n\u2022 times when they lose consciousness or have a lack of awareness \n\u2022 fits \u2013 this may be when they have a fever \nThese side effects have happened very rarely with other vaccines against whooping cough. They \nusually happen within 2 to 3 days after vaccination. \n \n\nOther side effects include: \n \nVery common (these may occur with more than 1 in 10 doses of the vaccine) \n\u2022 feeling tired \n\u2022 loss of appetite \n\u2022 high temperature of 38\u00b0C or higher \n\u2022 swelling, pain and redness where the injection was given \n\u2022 unusual crying \n\u2022 feeling irritable or restless. \n \nCommon (these may occur in with up to 1 in 10 doses of the vaccine) \n\u2022 diarrhoea  \n\u2022 being sick (vomiting) \n\u2022 high temperature of more than 39.5\u00b0C \n\u2022 swelling larger than 5 cm or hard lump where the injection was given. \n \nUncommon (these may occur in up to 1 in 100 doses of the vaccine) \n\u2022 feeling sleepy \n\u2022 cough \n\u2022 itching (dermatitis), rash \n\u2022 large swelling at the injected limb \n\u2022 feeling nervous. \n \nVery rare (these may occur with up to 1 in 10,000 doses of the vaccine) \n\u2022 in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal \n\nbetween breaths may occur for 2-3 days after vaccination \n\u2022 temporarily stopping breathing (apnoea)  \n\n21 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n\u2022 lumpy rash (hives) \n\u2022 swelling of the whole injected limb. \n \nIf any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please \ntell your doctor or pharmacist. \n \n\n \n5.  HHOW TO STORE INFANRIX PENTA \n \n\u2022 Keep out of the reach and sight of children. \n\u2022 Do not use Infanrix Penta after the expiry date which is stated on the carton. The expiry date \n\nrefers to the last day of that month. \n\u2022 Store in a refrigerator (2\u00b0C \u2013 8\u00b0C). \n\u2022 Store in the original package in order to protect from light. \n\u2022 Do not freeze. Freezing destroys the vaccine. \n\u2022 Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist \n\nhow to dispose of medicines no longer required. These measures will help to protect the \nenvironment. \n\n \n6.  FURTHER INFORMATION \n \nWhat Infanrix Penta contains \n \nThe active substances are: \n\nDiphtheria toxoid1 not less than 30 IU \nTetanus toxoid1 not less than 40 IU \nBordetella pertussis antigens \n Pertussis toxoid1 25 micrograms \n Filamentous Haemagglutinin1 25 micrograms \n Pertactin1 8 micrograms \nHepatitis B surface antigen2,3 10 micrograms \nPoliovirus (inactivated) \n\ntype 1 (Mahoney strain) 4 40 D-antigen unit \ntype 2 (MEF-1 strain) 4 8 D-antigen unit \ntype 3 (Saukett strain) 4 32 D-antigen unit \n\n \n1adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+\n2produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology \n3adsorbed on aluminium phosphate (AlPO4) 0.2 milligrams Al3+ \n4propagated in VERO cells \n\n \nThe other ingredients in Infanrix Penta are: sodium chloride (NaCl), medium 199 containing \nprincipally amino acids, mineral salts, vitamins and water for injections. \n \nWhat Infanrix Penta looks like and contents of the pack \n \n\u2022 Infanrix Penta is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml).  \n\u2022 Infanrix Penta is available in packs of 1, 10, 20 and 50 with or without needles. \n\u2022 Not all pack sizes may be marketed. \n \nMarketing Authorisation Holder and Manufacturer \n \nGlaxoSmithKline Biologicals s.a. \nRue de l\u2019Institut 89 \nB-1330 Rixensart \nBelgium \n\n22 \n\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n \nFor any information about this medicine, please contact the local representative of the Marketing \nAuthorisation Holder: \n \nBelgi\u00eb/Belgique/Belgien \nGlaxoSmithKline s.a./n.v. \nT\u00e9l/Tel: + 32 2 656 21 11 \n \n\nLuxembourg/Luxemburg \nGlaxoSmithKline s.a./n.v. \nT\u00e9l/Tel: + 32 2 656 21 11 \n\n\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f \n\u0413\u043b\u0430\u043a\u0441\u043e\u0421\u043c\u0438\u0442\u041a\u043b\u0430\u0439\u043d \u0415\u041e\u041e\u0414 \n\u0443\u043b. \u0414\u0438\u043c\u0438\u0442\u044a\u0440 \u041c\u0430\u043d\u043e\u0432 \u0431\u043b.10 \n\u0421\u043e\u0444\u0438\u044f 1408 \n\u0422\u0435\u043b. + 359 2 953 10 34 \n \n\nMagyarorsz\u00e1g \nGlaxoSmithKline Kft. \nTel.: + 36-1-2255300 \n \n \n\n\u010cesk\u00e1 republika \nGlaxoSmithKline s.r.o. \nTel: + 420 222 001 111 \ngsk.czmail@gsk.com \n \n\nMalta \nGlaxoSmithKline Malta \nTel: + 356 21 238131 \n \n\nDanmark \nGlaxoSmithKline Pharma A/S \nTlf: + 45 36 35 91 00 \ndk-info@gsk.com\n \n\nNederland \nGlaxoSmithKline BV \nTel: + 31 (0)30 69 38 100 \nnlinfo@gsk.com \n\nDeutschland \nGlaxoSmithKline GmbH & Co. KG \nTel: + 49 (0)89 360448701 \nprodukt.info@gsk.com \n \n\nNorge \nGlaxoSmithKline AS \nTlf: + 47 22 70 20 00 \nfirmapost@gsk.no \n \n\nEesti \nGlaxoSmithKline Eesti O\u00dc  \nTel: +372 667 6900 \nestonia@gsk.com \n \n\n\u00d6sterreich \nGlaxoSmithKline Pharma GmbH. \nTel: + 43 1 970 75-0 \nat.info@gsk.com  \n \n\n\u0395\u03bb\u03bb\u03ac\u03b4\u03b1 \nGlaxoSmithKline A.E.B.E. \nT\u03b7\u03bb: + 30 210 68 82 100 \n \n\nPolska \nGSK Commercial Sp. z.o.o. \nTel.: + 48 (22) 576 9000 \n \n\nEspa\u00f1a \nGlaxoSmithKline, S.A. \nTel: + 34 902 202 700 \nes-ci@gsk.com  \n \n\nPortugal \nSmith Kline & French Portuguesa, Produtos \nFarmac\u00eauticos, Lda. \nTel: + 351 21 412 95 00 \nFI.PT@gsk.com \n \n\nFrance \nLaboratoire GlaxoSmithKline \nT\u00e9l: + 33 (0) 1 39 17 84 44 \ndiam@gsk.com \n \n\nRom\u00e2nia \nGlaxoSmithKline (GSK) SRL \nTel: +40 (0)21 3028 208 \n \n\nIreland \nGlaxoSmithKline (Ireland) Ltd \nTel: + 353 (0)1 4955000 \n \n\nSlovenija \nGlaxoSmithKline d.o.o. \nTel: + 386 (0) 1 280 25 00 \n medical.x.si@gsk.com \n \n\n\u00cdsland \nGlaxoSmithKline ehf. \nS\u00edmi: +354-530 3700 \n\nSlovensk\u00e1 republika \nGlaxoSmithKline Slovakia s.r.o. \nTel: + 421 (0)2 48 26 11 11 \n\n23 \n\nmailto:dk-info@gsk.com\n\n\nMe\ndic\n\nina\nl p\n\nrod\nuc\n\nt n\no l\n\non\nge\n\nr a\nuth\n\nori\nse\n\nd\n\n recepcia.sk@gsk.com \n \n\nItalia \nGlaxoSmithKline S.p.A. \nTel:+ 39 04 59 21 81 11 \n \n\nSuomi/Finland \nGlaxoSmithKline Oy \nPuh/Tel: + 358 10 30 30 30 \nFinland.tuoteinfo@gsk.com  \n \n\n\u039a\u03cd\u03c0\u03c1\u03bf\u03c2 \nGlaxoSmithKline (Cyprus) Ltd \n\u03a4\u03b7\u03bb: + 357 22 39 70 00 \n \n \n\nSverige \nGlaxoSmithKline AB \nTel: + 46 (0)8 638 93 00 \ninfo.produkt@gsk.com \n\nLatvija \nGlaxoSmithKline Latvia SIA \nTel: + 371 67312687 \nlv-epasts@gsk.com \n \n\nUnited Kingdom \nGlaxoSmithKline UK \nTel: + 44 (0)808 100 9997 \ncustomercontactuk@gsk.com \n \n\nLietuva \nGlaxoSmithKline Lietuva UAB \nTel. +370 5 264 90 00 \ninfo.lt@gsk.com \n\n \n\n \nThis leaflet was last approved in \n \nDetailed information on this medicine is available on the European Medicines Agency (EMA) web \nsite: http://www.ema.europa.eu/. \n------------------------------------------------------------------------------------------------------------------------------- \n \nThe following information is intended for medical or healthcare professionals only: \n \nUpon storage, a white deposit and clear supernatant can be observed. This does not constitute a sign of \ndeterioration. \n \nThe syringe should be well shaken in order to obtain a homogeneous turbid white suspension.  \n \nThe diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis (DTPa-HBV-IPV) \nsuspension should be inspected visually for any foreign particulate matter and/or variation of physical \naspect. In the event of either being observed, discard the container.  \n\n24 \n\nhttp://www.ema.europa.eu/\n\n\tSUMMARY OF PRODUCT CHARACTERISTICS\n\tA. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE \n\tB. CONDITIONS OF THE MARKETING AUTHORISATION\n\tA. LABELLING\n\tB. PACKAGE LEAFLET", "Section_1": {"Title": "1. what infanrix penta is and what it is used for", "Section_Content": "infanrix penta is a vaccine used to protect your child again five diseases: diphtheria - a serious bacterial infection that mainly affects the airways and sometimes the skin. the airways become swollen causing serious breathing problems and sometimes suffocation. the bacteria also release a poison. this can cause nerve damage, heart problems, and even death. tetanus - tetanus bacteria enter the body through cuts, scratches or wounds in the skin. wounds that are more likely to get tetanus infection are burns, fractures, deep wounds or wounds that have soil, dust, horse manure or wood splinters in them. the bacteria release a poison. this can cause muscle stiffness, painful muscle spasms, fits and even death. the muscle spasms can be strong enough to cause bone fractures of the spine. whooping cough (pertussis) - a highly infectious illness that affects the airways. it causes severe coughing that may lead to problems with breathing. the coughing often has a \"whooping\" sound. the cough may last for one to two months or longer. whooping cough can also cause ear infections, chest infections (bronchitis) which may last a long time, lung infections (pneumonia), fits, brain damage and even death. hepatitis b - is caused by the hepatitis b virus. it makes the liver swollen. the virus is found in body fluids such as in the vagina, blood, semen, or spit (saliva) of infected people. polio - a viral infection. polio is often only a mild illness. however, sometimes it can be very serious and cause permanent damage or even death. polio can make the muscles unable to move (paralysis). this includes the muscles needed for breathing and walking. the arms or legs affected by the disease may be painfully twisted (deformed). how the vaccine works infanrix penta helps your child's body make its own protection (antibodies). this will protect your child against these diseases. as with all vaccines, infanrix penta may not fully protect all children who are vaccinated. the vaccine cannot cause the diseases that it protects your child from.", "Entity_Recognition": [{"Text": "infanrix penta", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 20, "BeginOffset": 0, "EndOffset": 14, "Score": 0.5191085338592529, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "a vaccine", "Type": "TREATMENT", "BeginOffset": 18, "EndOffset": 27}, {"Id": 22, "BeginOffset": 76, "EndOffset": 86, "Score": 0.9251194000244141, "Text": "diphtheria", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8596243262290955}]}, {"Text": "a serious bacterial infection", "Type": "PROBLEM", "BeginOffset": 89, "EndOffset": 118}, {"Id": 0, "BeginOffset": 169, "EndOffset": 173, "Score": 0.9813715815544128, "Text": "skin", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 24, "BeginOffset": 194, "EndOffset": 201, "Score": 0.956504762172699, "Text": "swollen", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.617060124874115}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9813715815544128, "RelationshipScore": 0.9555705785751343, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 0, "BeginOffset": 169, "EndOffset": 173, "Text": "skin", "Category": "ANATOMY", "Traits": []}]}, {"Text": "serious breathing problems", "Type": "PROBLEM", "BeginOffset": 210, "EndOffset": 236}, {"Id": 26, "BeginOffset": 251, "EndOffset": 262, "Score": 0.6094632744789124, "Text": "suffocation", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Text": "the bacteria", "Type": "PROBLEM", "BeginOffset": 264, "EndOffset": 276}, {"Id": 28, "BeginOffset": 315, "EndOffset": 327, "Score": 0.9555217027664185, "Text": "nerve damage", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9093255996704102}]}, {"Id": 29, "BeginOffset": 329, "EndOffset": 343, "Score": 0.9367737770080566, "Text": "heart problems", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5740721821784973}, {"Name": "DIAGNOSIS", "Score": 0.5804852247238159}]}, {"Text": "even death", "Type": "PROBLEM", "BeginOffset": 349, "EndOffset": 359}, {"Text": "tetanus", "Type": "TREATMENT", "BeginOffset": 361, "EndOffset": 368}, {"Text": "tetanus bacteria", "Type": "PROBLEM", "BeginOffset": 371, "EndOffset": 387}, {"Id": 3, "BeginOffset": 398, "EndOffset": 402, "Score": 0.6864777207374573, "Text": "body", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 32, "BeginOffset": 417, "EndOffset": 426, "Score": 0.519570529460907, "Text": "scratches", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.6864777207374573, "RelationshipScore": 0.9909787178039551, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 3, "BeginOffset": 398, "EndOffset": 402, "Text": "body", "Category": "ANATOMY", "Traits": []}]}, {"Text": "wounds in the skin", "Type": "PROBLEM", "BeginOffset": 430, "EndOffset": 448}, {"Id": 34, "BeginOffset": 450, "EndOffset": 456, "Score": 0.985926628112793, "Text": "wounds", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8623741269111633}]}, {"Text": "tetanus infection", "Type": "PROBLEM", "BeginOffset": 485, "EndOffset": 502}, {"Id": 36, "BeginOffset": 507, "EndOffset": 512, "Score": 0.9753687381744385, "Text": "burns", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7266367077827454}]}, {"Id": 37, "BeginOffset": 514, "EndOffset": 523, "Score": 0.9978410005569458, "Text": "fractures", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9314308762550354}]}, {"Id": 38, "BeginOffset": 525, "EndOffset": 536, "Score": 0.5813204646110535, "Text": "deep wounds", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8199034929275513}]}, {"Id": 39, "BeginOffset": 540, "EndOffset": 546, "Score": 0.995185911655426, "Text": "wounds", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7903092503547668}]}, {"Text": "the bacteria", "Type": "PROBLEM", "BeginOffset": 609, "EndOffset": 621}, {"Id": 40, "BeginOffset": 655, "EndOffset": 671, "Score": 0.8024795055389404, "Text": "muscle stiffness", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8439153432846069}]}, {"Id": 41, "BeginOffset": 673, "EndOffset": 694, "Score": 0.5862557291984558, "Text": "painful muscle spasms", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.7619346380233765}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9866594076156616, "RelationshipScore": 0.6755928993225098, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 6, "BeginOffset": 681, "EndOffset": 687, "Text": "muscle", "Category": "ANATOMY", "Traits": []}]}, {"Id": 6, "BeginOffset": 681, "EndOffset": 687, "Score": 0.9866594076156616, "Text": "muscle", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "even death", "Type": "PROBLEM", "BeginOffset": 705, "EndOffset": 715}, {"Text": "the muscle spasms", "Type": "PROBLEM", "BeginOffset": 717, "EndOffset": 734}, {"Text": "bone fractures of the spine", "Type": "PROBLEM", "BeginOffset": 765, "EndOffset": 792}, {"Id": 45, "BeginOffset": 794, "EndOffset": 808, "Score": 0.9251745939254761, "Text": "whooping cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.40703439712524414}, {"Name": "DIAGNOSIS", "Score": 0.5780105590820312}]}, {"Id": 46, "BeginOffset": 810, "EndOffset": 819, "Score": 0.7645280957221985, "Text": "pertussis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.6108735203742981}]}, {"Text": "a highly infectious illness", "Type": "PROBLEM", "BeginOffset": 823, "EndOffset": 850}, {"Text": "severe coughing", "Type": "PROBLEM", "BeginOffset": 887, "EndOffset": 902}, {"Id": 49, "BeginOffset": 920, "EndOffset": 943, "Score": 0.40286654233932495, "Text": "problems with breathing", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8758980631828308}]}, {"Text": "the coughing", "Type": "PROBLEM", "BeginOffset": 945, "EndOffset": 957}, {"Id": 51, "BeginOffset": 971, "EndOffset": 986, "Score": 0.6546783447265625, "Text": "whooping\" sound", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.840446412563324}], "Attributes": [{"Type": "ACUITY", "Score": 0.491456001996994, "RelationshipScore": 0.8056119084358215, "RelationshipType": "ACUITY", "Id": 53, "BeginOffset": 1002, "EndOffset": 1028, "Text": "last for one to two months", "Category": "MEDICAL_CONDITION", "Traits": []}]}, {"Text": "the cough", "Type": "PROBLEM", "BeginOffset": 988, "EndOffset": 997}, {"Id": 54, "BeginOffset": 1040, "EndOffset": 1054, "Score": 0.9355154633522034, "Text": "whooping cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.65679931640625}]}, {"Id": 55, "BeginOffset": 1070, "EndOffset": 1084, "Score": 0.9858875870704651, "Text": "ear infections", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8094893097877502}]}, {"Text": "chest infections (bronchitis)", "Type": "PROBLEM", "BeginOffset": 1086, "EndOffset": 1115}, {"Text": "lung infections (pneumonia)", "Type": "PROBLEM", "BeginOffset": 1144, "EndOffset": 1171}, {"Id": 60, "BeginOffset": 1179, "EndOffset": 1191, "Score": 0.8594452738761902, "Text": "brain damage", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.925410270690918}]}, {"Text": "even death", "Type": "PROBLEM", "BeginOffset": 1196, "EndOffset": 1206}, {"Text": "hepatitis b", "Type": "PROBLEM", "BeginOffset": 1208, "EndOffset": 1219}, {"Text": "the hepatitis b virus", "Type": "PROBLEM", "BeginOffset": 1235, "EndOffset": 1256}, {"Text": "the liver swollen", "Type": "PROBLEM", "BeginOffset": 1267, "EndOffset": 1284}, {"Text": "the virus", "Type": "PROBLEM", "BeginOffset": 1286, "EndOffset": 1295}, {"Id": 15, "BeginOffset": 1335, "EndOffset": 1341, "Score": 0.9398702383041382, "Text": "vagina", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "spit", "Type": "PROBLEM", "BeginOffset": 1360, "EndOffset": 1364}, {"Id": 65, "BeginOffset": 1377, "EndOffset": 1392, "Score": 0.47871536016464233, "Text": "infected people", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.4697541296482086}]}, {"Id": 66, "BeginOffset": 1394, "EndOffset": 1399, "Score": 0.9569593667984009, "Text": "polio", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8728265166282654}]}, {"Text": "a viral infection", "Type": "PROBLEM", "BeginOffset": 1402, "EndOffset": 1419}, {"Id": 68, "BeginOffset": 1421, "EndOffset": 1426, "Score": 0.9553018808364868, "Text": "polio", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8118234872817993}]}, {"Text": "a mild illness", "Type": "PROBLEM", "BeginOffset": 1441, "EndOffset": 1455}, {"Id": 70, "BeginOffset": 1509, "EndOffset": 1525, "Score": 0.7513539791107178, "Text": "permanent damage", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.4438720643520355}, {"Name": "DIAGNOSIS", "Score": 0.5270385146141052}]}, {"Text": "even death", "Type": "PROBLEM", "BeginOffset": 1529, "EndOffset": 1539}, {"Id": 72, "BeginOffset": 1541, "EndOffset": 1546, "Score": 0.9404249787330627, "Text": "polio", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7184885144233704}]}, {"Id": 16, "BeginOffset": 1560, "EndOffset": 1567, "Score": 0.9703008532524109, "Text": "muscles", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 73, "BeginOffset": 1568, "EndOffset": 1582, "Score": 0.4815095067024231, "Text": "unable to move", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5687349438667297}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9703008532524109, "RelationshipScore": 0.9997203946113586, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 16, "BeginOffset": 1560, "EndOffset": 1567, "Text": "muscles", "Category": "ANATOMY", "Traits": []}]}, {"Id": 74, "BeginOffset": 1584, "EndOffset": 1593, "Score": 0.9625281691551208, "Text": "paralysis", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.4639133810997009}, {"Name": "DIAGNOSIS", "Score": 0.477761447429657}]}, {"Id": 17, "BeginOffset": 1614, "EndOffset": 1621, "Score": 0.981580913066864, "Text": "muscles", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 75, "BeginOffset": 1633, "EndOffset": 1642, "Score": 0.4672583043575287, "Text": "breathing", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 18, "BeginOffset": 1660, "EndOffset": 1664, "Score": 0.9916806817054749, "Text": "arms", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 19, "BeginOffset": 1668, "EndOffset": 1672, "Score": 0.9829960465431213, "Text": "legs", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "the disease", "Type": "PROBLEM", "BeginOffset": 1685, "EndOffset": 1696}, {"Text": "the vaccine works infanrix penta", "Type": "TREATMENT", "BeginOffset": 1738, "EndOffset": 1770}, {"Text": "these diseases", "Type": "PROBLEM", "BeginOffset": 1870, "EndOffset": 1884}, {"Text": "all vaccines", "Type": "TREATMENT", "BeginOffset": 1894, "EndOffset": 1906}, {"Id": 21, "BeginOffset": 1908, "EndOffset": 1922, "Score": 0.21438229084014893, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "the vaccine", "Type": "TREATMENT", "BeginOffset": 1978, "EndOffset": 1989}, {"Text": "the diseases", "Type": "PROBLEM", "BeginOffset": 2003, "EndOffset": 2015}]}, "Section_2": {"Title": "2. before your child receives infanrix penta", "Section_Content": "infanrix penta should not be given if: your child is allergic (hypersensitive) to - infanrix penta, or any ingredients in infanrix penta (listed in section 6) - neomycin or polymyxin (antibiotics). signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue. your child has had an allergic reaction to any vaccine against diphtheria, tetanus, whooping cough, hepatitis b or polio. your child has had problems of the nervous system within 7 days after previous vaccination with a vaccine against whooping cough. your child has a severe infection with a high temperature (over 38). a minor infection such as a cold should not be a problem, but talk to your doctor first. infanrix penta should not be given if any of the above apply to your child. if you are not sure, talk to your doctor or pharmacist before your child is given infanrix penta. take special care with infanrix penta check with your doctor or pharmacist before your child is given this vaccine if: after previously having infanrix penta or another vaccine against whooping cough, your child had any problems, especially: - a high temperature (over 40) within 48 hours of vaccination - a collapse or 'shock-like' state within 48 hours of vaccination - persistent crying lasting 3 hours or more within 48 hours of vaccination - fits with or without a high temperature within 3 days of vaccination your child has an undiagnosed or progressive disease of the brain or epilepsy which is not controlled. after control of the disease the vaccine can be given. your child has a bleeding problem or bruises easily your child tends to have fits when they have a fever, or if there is a history of this in the family. if any of the above apply to your child (or you are not sure), talk to your doctor or pharmacist before your child is given infanrix penta. using other medicines or vaccines please tell your doctor if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently had any other vaccine. important information about some of the ingredients of infanrix penta this vaccine contains neomycin and polymyxin (antibiotics). please tell your doctor if your child has had an allergic reaction to these ingredients.", "Entity_Recognition": [{"Text": "infanrix penta", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 5, "BeginOffset": 0, "EndOffset": 14, "Score": 0.5766080617904663, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "allergic", "Type": "PROBLEM", "BeginOffset": 53, "EndOffset": 61}, {"Id": 18, "BeginOffset": 63, "EndOffset": 77, "Score": 0.7592079043388367, "Text": "hypersensitive", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.5314022302627563}]}, {"Id": 6, "BeginOffset": 84, "EndOffset": 98, "Score": 0.44023633003234863, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 7, "BeginOffset": 122, "EndOffset": 136, "Score": 0.4374181628227234, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "6", "Type": "NUMBER", "BeginOffset": 156, "EndOffset": 157}, {"Id": 8, "BeginOffset": 161, "EndOffset": 169, "Score": 0.9932475090026855, "Text": "neomycin", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "polymyxin (antibiotics", "Type": "TREATMENT", "BeginOffset": 173, "EndOffset": 195}, {"Text": "an allergic reaction", "Type": "PROBLEM", "BeginOffset": 207, "EndOffset": 227}, {"Id": 20, "BeginOffset": 240, "EndOffset": 255, "Score": 0.5342926383018494, "Text": "itchy skin rash", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.6207486391067505}]}, {"Id": 0, "BeginOffset": 246, "EndOffset": 250, "Score": 0.9776010513305664, "Text": "skin", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 21, "BeginOffset": 257, "EndOffset": 276, "Score": 0.9964045286178589, "Text": "shortness of breath", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.8654859066009521}]}, {"Text": "swelling of the face or tongue", "Type": "PROBLEM", "BeginOffset": 281, "EndOffset": 311}, {"Text": "an allergic reaction", "Type": "PROBLEM", "BeginOffset": 332, "EndOffset": 352}, {"Text": "any vaccine", "Type": "TREATMENT", "BeginOffset": 356, "EndOffset": 367}, {"Id": 24, "BeginOffset": 376, "EndOffset": 386, "Score": 0.8448031544685364, "Text": "diphtheria", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8013030290603638}]}, {"Id": 11, "BeginOffset": 388, "EndOffset": 395, "Score": 0.7342774868011475, "Text": "tetanus", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 25, "BeginOffset": 397, "EndOffset": 411, "Score": 0.9041179418563843, "Text": "whooping cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7499341368675232}]}, {"Id": 26, "BeginOffset": 413, "EndOffset": 424, "Score": 0.9213442206382751, "Text": "hepatitis b", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.8655664920806885}]}, {"Id": 27, "BeginOffset": 428, "EndOffset": 433, "Score": 0.981132447719574, "Text": "polio", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9129283428192139}]}, {"Id": 3, "BeginOffset": 470, "EndOffset": 484, "Score": 0.41493767499923706, "Text": "nervous system", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "7", "Type": "NUMBER", "BeginOffset": 492, "EndOffset": 493}, {"Text": "previous vaccination", "Type": "TREATMENT", "BeginOffset": 505, "EndOffset": 525}, {"Text": "a vaccine", "Type": "TREATMENT", "BeginOffset": 531, "EndOffset": 540}, {"Id": 28, "BeginOffset": 549, "EndOffset": 563, "Score": 0.8822532892227173, "Text": "whooping cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.66628497838974}]}, {"Text": "a severe infection", "Type": "PROBLEM", "BeginOffset": 580, "EndOffset": 598}, {"Text": "a high temperature", "Type": "PROBLEM", "BeginOffset": 604, "EndOffset": 622}, {"Id": 54, "BeginOffset": 624, "EndOffset": 628, "Score": 0.7254594564437866, "Text": "over", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_TEST_NAME", "Traits": [], "Attributes": [{"Type": "TEST_NAME", "Score": 0.47092512249946594, "RelationshipScore": 0.7519101500511169, "RelationshipType": "OVERLAP", "Id": 43, "BeginOffset": 611, "EndOffset": 622, "Text": "temperature", "Category": "TEST_TREATMENT_PROCEDURE", "Traits": []}]}, {"Text": "a minor infection", "Type": "PROBLEM", "BeginOffset": 634, "EndOffset": 651}, {"Id": 31, "BeginOffset": 662, "EndOffset": 666, "Score": 0.5064025521278381, "Text": "cold", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 12, "BeginOffset": 723, "EndOffset": 737, "Score": 0.4934157729148865, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 13, "BeginOffset": 881, "EndOffset": 895, "Score": 0.8197945952415466, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 14, "BeginOffset": 920, "EndOffset": 934, "Score": 0.2914886176586151, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 44, "BeginOffset": 1004, "EndOffset": 1011, "Score": 0.5189734697341919, "Text": "vaccine", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 55, "BeginOffset": 1022, "EndOffset": 1032, "Score": 0.9999963045120239, "Text": "previously", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_DX_NAME", "Traits": [], "Attributes": [{"Type": "DX_NAME", "Score": 0.2913472652435303, "RelationshipScore": 0.6802959442138672, "RelationshipType": "OVERLAP", "Id": 32, "BeginOffset": 1040, "EndOffset": 1054, "Text": "infanrix penta", "Category": "MEDICAL_CONDITION", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.4482605457305908}]}]}, {"Id": 15, "BeginOffset": 1040, "EndOffset": 1054, "Score": 0.6334194540977478, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 45, "BeginOffset": 1066, "EndOffset": 1073, "Score": 0.49018731713294983, "Text": "vaccine", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 33, "BeginOffset": 1082, "EndOffset": 1096, "Score": 0.9114350080490112, "Text": "whooping cough", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.41795578598976135}, {"Name": "DIAGNOSIS", "Score": 0.590994119644165}]}, {"Text": "a high temperature", "Type": "PROBLEM", "BeginOffset": 1141, "EndOffset": 1159}, {"Text": "40", "Type": "NUMBER", "BeginOffset": 1166, "EndOffset": 1168}, {"Text": "48", "Type": "NUMBER", "BeginOffset": 1177, "EndOffset": 1179}, {"Id": 47, "BeginOffset": 1189, "EndOffset": 1200, "Score": 0.38201966881752014, "Text": "vaccination", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Id": 34, "BeginOffset": 1205, "EndOffset": 1235, "Score": 0.25336942076683044, "Text": "collapse or 'shock-like' state", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": []}, {"Id": 56, "BeginOffset": 1236, "EndOffset": 1242, "Score": 0.4803849458694458, "Text": "within", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_TREATMENT_NAME", "Traits": [], "Attributes": [{"Type": "TREATMENT_NAME", "Score": 0.4367709755897522, "RelationshipScore": 0.5639404654502869, "RelationshipType": "OVERLAP", "Id": 48, "BeginOffset": 1255, "EndOffset": 1266, "Text": "vaccination", "Category": "TEST_TREATMENT_PROCEDURE", "Traits": []}]}, {"Text": "48", "Type": "NUMBER", "BeginOffset": 1243, "EndOffset": 1245}, {"Id": 48, "BeginOffset": 1255, "EndOffset": 1266, "Score": 0.4367709755897522, "Text": "vaccination", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "persistent crying", "Type": "PROBLEM", "BeginOffset": 1269, "EndOffset": 1286}, {"Text": "3", "Type": "NUMBER", "BeginOffset": 1295, "EndOffset": 1296}, {"Text": "48", "Type": "NUMBER", "BeginOffset": 1318, "EndOffset": 1320}, {"Id": 49, "BeginOffset": 1330, "EndOffset": 1341, "Score": 0.517257809638977, "Text": "vaccination", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "a high temperature", "Type": "PROBLEM", "BeginOffset": 1365, "EndOffset": 1383}, {"Text": "3", "Type": "NUMBER", "BeginOffset": 1391, "EndOffset": 1392}, {"Id": 50, "BeginOffset": 1401, "EndOffset": 1412, "Score": 0.5703271627426147, "Text": "vaccination", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "progressive disease of the brain", "Type": "PROBLEM", "BeginOffset": 1446, "EndOffset": 1478}, {"Id": 37, "BeginOffset": 1482, "EndOffset": 1490, "Score": 0.9708050489425659, "Text": "epilepsy", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.9611474871635437}], "Attributes": [{"Type": "SYSTEM_ORGAN_SITE", "Score": 0.9616830945014954, "RelationshipScore": 0.9853223562240601, "RelationshipType": "SYSTEM_ORGAN_SITE", "Id": 4, "BeginOffset": 1473, "EndOffset": 1478, "Text": "brain", "Category": "ANATOMY", "Traits": []}]}, {"Text": "the disease", "Type": "PROBLEM", "BeginOffset": 1533, "EndOffset": 1544}, {"Text": "the vaccine", "Type": "TREATMENT", "BeginOffset": 1545, "EndOffset": 1556}, {"Text": "a bleeding problem", "Type": "PROBLEM", "BeginOffset": 1586, "EndOffset": 1604}, {"Id": 39, "BeginOffset": 1608, "EndOffset": 1615, "Score": 0.8457111716270447, "Text": "bruises", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "SYMPTOM", "Score": 0.5954091548919678}]}, {"Text": "a fever", "Type": "PROBLEM", "BeginOffset": 1668, "EndOffset": 1675}, {"Id": 16, "BeginOffset": 1849, "EndOffset": 1863, "Score": 0.760235071182251, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "other medicines", "Type": "TREATMENT", "BeginOffset": 1871, "EndOffset": 1886}, {"Id": 52, "BeginOffset": 1890, "EndOffset": 1898, "Score": 0.8512519598007202, "Text": "vaccines", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "any other medicines", "Type": "TREATMENT", "BeginOffset": 1969, "EndOffset": 1988}, {"Text": "medicines", "Type": "TREATMENT", "BeginOffset": 2000, "EndOffset": 2009}, {"Id": 66, "BeginOffset": 2049, "EndOffset": 2057, "Score": 0.9999994039535522, "Text": "recently", "Category": "TIME_EXPRESSION", "Type": "TIME_TO_TREATMENT_NAME", "Traits": [], "Attributes": [{"Type": "TREATMENT_NAME", "Score": 0.457577645778656, "RelationshipScore": 0.8282629251480103, "RelationshipType": "OVERLAP", "Id": 63, "BeginOffset": 2072, "EndOffset": 2079, "Text": "vaccine", "Category": "TEST_TREATMENT_PROCEDURE", "Traits": []}]}, {"Id": 63, "BeginOffset": 2072, "EndOffset": 2079, "Score": 0.457577645778656, "Text": "vaccine", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "TREATMENT_NAME", "Traits": []}, {"Text": "infanrix penta this vaccine", "Type": "TREATMENT", "BeginOffset": 2136, "EndOffset": 2163}, {"Text": "polymyxin (antibiotics", "Type": "TREATMENT", "BeginOffset": 2186, "EndOffset": 2208}, {"Text": "an allergic reaction", "Type": "PROBLEM", "BeginOffset": 2257, "EndOffset": 2277}, {"Text": "these ingredients", "Type": "TREATMENT", "BeginOffset": 2281, "EndOffset": 2298}]}, "Section_3": {"Title": "3. how infanrix penta is given", "Section_Content": "how much is given your child will have a total of two or three injections with at least 1 month between each injection. you will be told by the doctor or nurse when your child should come back for their next injections. if additional injections (boosters) are necessary, the doctor will tell you. how the vaccine is given infanrix penta will be given as an injection into a muscle. the vaccine should never be given into a blood vessel or into the skin. if your child misses a dose if your child misses an injection which is due, it is important that you make another appointment. make sure your child finishes the complete vaccination course. if not, your child may not be fully protected against the diseases.", "Entity_Recognition": [{"Text": "infanrix penta", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 5, "BeginOffset": 63, "EndOffset": 73, "Score": 0.28197911381721497, "Text": "injections", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 88, "EndOffset": 89}, {"Id": 6, "BeginOffset": 109, "EndOffset": 118, "Score": 0.4509067237377167, "Text": "injection", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Text": "their next injections", "Type": "TREATMENT", "BeginOffset": 197, "EndOffset": 218}, {"Text": "additional injections (boosters)", "Type": "TREATMENT", "BeginOffset": 223, "EndOffset": 255}, {"Text": "the vaccine", "Type": "TREATMENT", "BeginOffset": 301, "EndOffset": 312}, {"Id": 3, "BeginOffset": 322, "EndOffset": 336, "Score": 0.6972070932388306, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "ROUTE_OR_MODE", "Score": 0.3381052613258362, "RelationshipScore": 0.9999873638153076, "RelationshipType": "ROUTE_OR_MODE", "Id": 4, "BeginOffset": 357, "EndOffset": 366, "Text": "injection", "Category": "MEDICATION", "Traits": []}]}, {"Id": 10, "BeginOffset": 357, "EndOffset": 366, "Score": 0.4589197635650635, "Text": "injection", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Id": 0, "BeginOffset": 374, "EndOffset": 380, "Score": 0.6577052474021912, "Text": "muscle", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Text": "the vaccine", "Type": "TREATMENT", "BeginOffset": 382, "EndOffset": 393}, {"Text": "a blood vessel", "Type": "TREATMENT", "BeginOffset": 421, "EndOffset": 435}, {"Id": 2, "BeginOffset": 448, "EndOffset": 452, "Score": 0.9812715649604797, "Text": "skin", "Category": "ANATOMY", "Type": "SYSTEM_ORGAN_SITE", "Traits": []}, {"Id": 12, "BeginOffset": 506, "EndOffset": 515, "Score": 0.6788842678070068, "Text": "injection", "Category": "TEST_TREATMENT_PROCEDURE", "Type": "PROCEDURE_NAME", "Traits": []}, {"Text": "the complete vaccination course", "Type": "TREATMENT", "BeginOffset": 611, "EndOffset": 642}, {"Text": "the diseases", "Type": "PROBLEM", "BeginOffset": 698, "EndOffset": 710}]}, "Section_4": {"Title": "4. possible side effects", "Section_Content": null, "Entity_Recognition": null}, "Section_5": {"Title": "5. how to store infanrix penta", "Section_Content": null, "Entity_Recognition": null}, "Section_6": {"Title": "6. further information", "Section_Content": "what infanrix penta contains the active substances are: diphtheria toxoid1 not less than 30 iu tetanus toxoid1 not less than 40 iu bordetella pertussis antigens pertussis toxoid1 25 micrograms filamentous haemagglutinin1 25 micrograms pertactin1 8 micrograms hepatitis b surface antigen2,3 10 micrograms poliovirus (inactivated) type 1 (mahoney strain) 4 40 d-antigen unit type 2 (mef-1 strain) 4 8 d-antigen unit type 3 (saukett strain) 4 32 d-antigen unit 1adsorbed on aluminium hydroxide, hydrated (al(oh)3) 0.5 milligrams al3+ 2produced in yeast cells (saccharomyces cerevisiae) by recombinant dna technology 3adsorbed on aluminium phosphate (alpo4) 0.2 milligrams al3+ 4propagated in vero cells the other ingredients in infanrix penta are: sodium chloride (nacl), medium 199 containing principally amino acids, mineral salts, vitamins and water for injections. what infanrix penta looks like and contents of the pack infanrix penta is a white, slightly milky liquid presented in a pre-filled syringe (0.5 ml). infanrix penta is available in packs of 1, 10, 20 and 50 with or without needles. not all pack sizes may be marketed.", "Entity_Recognition": [{"Text": "infanrix penta", "Type": "PRODUCT_NAME", "BeginOffset": 0, "EndOffset": 0}, {"Id": 0, "BeginOffset": 5, "EndOffset": 19, "Score": 0.3482743799686432, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 1, "BeginOffset": 56, "EndOffset": 74, "Score": 0.7455365657806396, "Text": "diphtheria toxoid1", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "30", "Type": "NUMBER", "BeginOffset": 89, "EndOffset": 91}, {"Id": 3, "BeginOffset": 95, "EndOffset": 110, "Score": 0.9062358140945435, "Text": "tetanus toxoid1", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.9581632614135742, "RelationshipScore": 1.0, "RelationshipType": "DOSAGE", "Id": 2, "BeginOffset": 89, "EndOffset": 94, "Text": "30 iu", "Category": "MEDICATION", "Traits": []}]}, {"Text": "40", "Type": "NUMBER", "BeginOffset": 125, "EndOffset": 127}, {"Text": "bordetella pertussis antigens pertussis toxoid1", "Type": "TREATMENT", "BeginOffset": 131, "EndOffset": 178}, {"Text": "25", "Type": "NUMBER", "BeginOffset": 179, "EndOffset": 181}, {"Id": 8, "BeginOffset": 193, "EndOffset": 220, "Score": 0.28166866302490234, "Text": "filamentous haemagglutinin1", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.9174774289131165, "RelationshipScore": 0.9924639463424683, "RelationshipType": "DOSAGE", "Id": 7, "BeginOffset": 179, "EndOffset": 192, "Text": "25 micrograms", "Category": "MEDICATION", "Traits": []}, {"Type": "DOSAGE", "Score": 0.9297743439674377, "RelationshipScore": 0.819823682308197, "RelationshipType": "DOSAGE", "Id": 9, "BeginOffset": 221, "EndOffset": 234, "Text": "25 micrograms", "Category": "MEDICATION", "Traits": []}]}, {"Text": "25", "Type": "NUMBER", "BeginOffset": 221, "EndOffset": 223}, {"Id": 10, "BeginOffset": 235, "EndOffset": 245, "Score": 0.8248661756515503, "Text": "pertactin1", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.9297743439674377, "RelationshipScore": 0.9943607449531555, "RelationshipType": "DOSAGE", "Id": 9, "BeginOffset": 221, "EndOffset": 234, "Text": "25 micrograms", "Category": "MEDICATION", "Traits": []}]}, {"Text": "8", "Type": "NUMBER", "BeginOffset": 246, "EndOffset": 247}, {"Id": 12, "BeginOffset": 259, "EndOffset": 287, "Score": 0.7821165323257446, "Text": "hepatitis b surface antigen2", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.9339197278022766, "RelationshipScore": 0.7663808465003967, "RelationshipType": "DOSAGE", "Id": 11, "BeginOffset": 246, "EndOffset": 258, "Text": "8 micrograms", "Category": "MEDICATION", "Traits": []}]}, {"Text": "3", "Type": "NUMBER", "BeginOffset": 288, "EndOffset": 289}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 290, "EndOffset": 292}, {"Id": 14, "BeginOffset": 304, "EndOffset": 314, "Score": 0.7928256988525391, "Text": "poliovirus", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.8167968988418579, "RelationshipScore": 0.9753545522689819, "RelationshipType": "DOSAGE", "Id": 13, "BeginOffset": 288, "EndOffset": 303, "Text": "3 10 micrograms", "Category": "MEDICATION", "Traits": []}]}, {"Id": 15, "BeginOffset": 316, "EndOffset": 327, "Score": 0.29717716574668884, "Text": "inactivated", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "type 1 (mahoney strain)", "Type": "PROBLEM", "BeginOffset": 329, "EndOffset": 352}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 334, "EndOffset": 335}, {"Text": "4", "Type": "NUMBER", "BeginOffset": 353, "EndOffset": 354}, {"Text": "40", "Type": "NUMBER", "BeginOffset": 355, "EndOffset": 357}, {"Text": "2", "Type": "NUMBER", "BeginOffset": 378, "EndOffset": 379}, {"Text": "mef", "Type": "TEST", "BeginOffset": 381, "EndOffset": 384}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 385, "EndOffset": 386}, {"Id": 34, "BeginOffset": 387, "EndOffset": 393, "Score": 0.6108967661857605, "Text": "strain", "Category": "MEDICAL_CONDITION", "Type": "DX_NAME", "Traits": [{"Name": "DIAGNOSIS", "Score": 0.7168278098106384}]}, {"Text": "4", "Type": "NUMBER", "BeginOffset": 395, "EndOffset": 396}, {"Text": "8", "Type": "NUMBER", "BeginOffset": 397, "EndOffset": 398}, {"Text": "d-antigen unit type 3 (saukett strain)", "Type": "TREATMENT", "BeginOffset": 399, "EndOffset": 437}, {"Text": "3", "Type": "NUMBER", "BeginOffset": 419, "EndOffset": 420}, {"Text": "4", "Type": "NUMBER", "BeginOffset": 438, "EndOffset": 439}, {"Text": "32", "Type": "NUMBER", "BeginOffset": 440, "EndOffset": 442}, {"Text": "aluminium hydroxide, hydrated (al(oh)", "Type": "TREATMENT", "BeginOffset": 471, "EndOffset": 508}, {"Text": "0.5", "Type": "NUMBER", "BeginOffset": 511, "EndOffset": 514}, {"Id": 18, "BeginOffset": 526, "EndOffset": 555, "Score": 0.2597982585430145, "Text": "al3+ 2produced in yeast cells", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": [], "Attributes": [{"Type": "DOSAGE", "Score": 0.29427292943000793, "RelationshipScore": 0.999997615814209, "RelationshipType": "DOSAGE", "Id": 17, "BeginOffset": 511, "EndOffset": 525, "Text": "0.5 milligrams", "Category": "MEDICATION", "Traits": []}]}, {"Id": 19, "BeginOffset": 557, "EndOffset": 581, "Score": 0.632940948009491, "Text": "saccharomyces cerevisiae", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "aluminium phosphate (alpo4)", "Type": "TREATMENT", "BeginOffset": 626, "EndOffset": 653}, {"Text": "0.2", "Type": "NUMBER", "BeginOffset": 654, "EndOffset": 657}, {"Id": 23, "BeginOffset": 725, "EndOffset": 739, "Score": 0.5071120262145996, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "sodium chloride (nacl)", "Type": "TREATMENT", "BeginOffset": 745, "EndOffset": 767}, {"Text": "199", "Type": "NUMBER", "BeginOffset": 776, "EndOffset": 779}, {"Id": 26, "BeginOffset": 803, "EndOffset": 814, "Score": 0.7356104850769043, "Text": "amino acids", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 27, "BeginOffset": 816, "EndOffset": 829, "Score": 0.918174147605896, "Text": "mineral salts", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Id": 28, "BeginOffset": 831, "EndOffset": 839, "Score": 0.735740065574646, "Text": "vitamins", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "water", "Type": "TREATMENT", "BeginOffset": 844, "EndOffset": 849}, {"Text": "injections", "Type": "TREATMENT", "BeginOffset": 854, "EndOffset": 864}, {"Text": "a white, slightly milky liquid", "Type": "PROBLEM", "BeginOffset": 940, "EndOffset": 970}, {"Text": "a pre-filled syringe", "Type": "TREATMENT", "BeginOffset": 984, "EndOffset": 1004}, {"Text": "0.5", "Type": "NUMBER", "BeginOffset": 1006, "EndOffset": 1009}, {"Id": 30, "BeginOffset": 1015, "EndOffset": 1029, "Score": 0.37005311250686646, "Text": "infanrix penta", "Category": "MEDICATION", "Type": "GENERIC_NAME", "Traits": []}, {"Text": "1", "Type": "NUMBER", "BeginOffset": 1055, "EndOffset": 1056}, {"Text": "10", "Type": "NUMBER", "BeginOffset": 1058, "EndOffset": 1060}, {"Text": "20", "Type": "NUMBER", "BeginOffset": 1062, "EndOffset": 1064}, {"Text": "50", "Type": "NUMBER", "BeginOffset": 1069, "EndOffset": 1071}]}}